FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA is announcing a leadership succession plan for the Office of Policy & Planning ahead of the impending retirement of Associate Commissioner William Hubbard
You may also be interested in...
The planned reorganization of FDA following Commissioner Mark McClellan's departure reflects an emphasis on interactions with Capitol Hill and the Administration
FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD
FDA Senior Economic Advisor Tomas Philipson, PhD, will work with Commissioner Mark McClellan, MD/PhD, to develop strategic initiatives